Answers are grounded in this paper and cite their sources.
Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for approximately 15% of all pediatric cancer-related deaths. While clinical staging systems provide a foundation for therapeutic decision-making, they fail to fully capture the complex interplay of genetic alterations, oncogenic signaling pathways, tumor microenvironmental dynamics, and developmental biology that collectively shape NB progression. Genomic profiling has identified recurrent driver events, including MYCN amplification, ALK mutations, ATRX and TERT dysregulation, and segmental chromosomal aberrations, which contribute to tumor aggressiveness, treatment resistance, and telomere maintenance mechanisms. Emerging therapeutic strategies are increasingly designed to target these molecular and cellular vulnerabilities. Ongoing clinical trials are evaluating ALK inhibitors, anti-GD2 antibodies, CAR-T cell therapies, and agents directed against NTRK, ROS1, KRAS, EGFR, and B7-H3, reflecting a paradigm shift toward precision medicine in NB. In this review, we provide a comprehensive overview of NB, encompassing classification systems, genetic and molecular pathogenesis, microenvironmental contributions, mechanisms of spontaneous regression, and current treatment strategies, which frame the rationale for novel, biology-driven clinical interventions.
No takes yet. Share an insight, caveat, or question.
Batur et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: